Skip to main content

Update WHO ART guideline 2019
Enrollment in this course is by invitation only

2 weeks self-paced course with latest updates WHO ART guideline
Enrollment in this course is by invitation only

About This Course

The development of WHO ART guidelines for low- and middle-income countries goes fast. In 2018, interim guidelines were published with an important role for dolutegravir, but a safety concern came up showing an increased risk of neural tube defects when dolutegravir is used at time of conception. In 2019 new safety and efficacy data about dolutegravir based treatment, new data on efavirenz 400mg as alternative first line, new developments for ART in children and neonates and new data about pretreatment drug resistance in adults and children became available.

Based on these latest data, WHO established and published the new 2019 ART guideline for adults, adolescents, children and neonates.

This course summarizes that guideline and provides you with the most relevant background information.

The course has been created for the AIDS Healthcare foundation and provides the healthcare workers with details of the 2019 WHO ART guideline.

What you will learn

  • ART coverage and drug resistance update
  • Background information for ART guideline
  • First-line treatment adults
  • First line treatment children
  • Second line treatment
  • Implementation issues
  • Contraceptive services

Course Staff

Course Staff Image #1

Clemens Richter, MD PhD

Frequently Asked Questions

What web browser should I use?

The platform works best with current versions of Chrome, Firefox or Safari, or with Internet Explorer version 9 and above.

Enrollment in this course is by invitation only